Stockscreener 앱 받기
39.60
17.08%
5.76
시간 외 거래:
39.56
-0.04
-0.10%
전일 마감가:
$33.84
열려 있는:
$34.38
하루 거래량:
24.60M
Relative Volume:
2.28
시가총액:
$15.47B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-4.5361
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
+11.10%
1개월 성능:
+34.49%
6개월 성능:
+17.78%
1년 성능:
+12.72%
1일 변동 폭
$34.05
$39.71
1주일 범위
$32.37
$39.71
52주 변동 폭
$22.28
$45.40
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
39.60 | 13.22B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna (NASDAQ:MRNA) Shares Up 7.1%Still a Buy? - MarketBeat
Moderna rallies after projecting better-than-expected 2025 sales - Sherwood News
Why Moderna Stock Strength Is Only Beginning: Technical Analysis - Barron's
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
Moderna (MRNA) Shares Surge by Nearly 13% - GuruFocus
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday - Benzinga
Moderna jumps 12% on 2025 projections - breakingthenews.net
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA) - Seeking Alpha
Moderna updates 2025 outlook and highlights pipeline progress - The Globe and Mail
Moderna says possible allergic reactions to Covid-19 vaccine under investigation - The Daily Star
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Providence Journal
Moderna chair says US assault on science is just beginning - The Daily Gazette
Commonwealth Fusion Systems Appoints Stephane Bancel, Moderna CEO, to Its Board of Directors - energynews
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape - The Chronicle-Journal
Moderna Chair Says US Assault on Science Is Just Beginning - Bloomberg.com
Commonwealth Fusion Systems Appoints Stephane Bancel To Board - citybiz
Moderna expects 2025 revenue of $1.9B, above guidance - Proactive financial news
Aug Decliners: Should you avoid Moderna Inc stock right now2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating - marketscreener.com
Why Moderna Stock Is Dropping After Good News - Barron's
Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year - marketscreener.com
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast - BioSpace
Moderna says its expects $1.9 billion in 2025 sales amid better-than-expected vaccination rate - Sherwood News
Moderna raises its forecasts and the stock rises before the opening of the US market - المتداول العربي
Moderna sees sales boost as COVID shots beat expectations - The Detroit News
Market movers: Synchrony Financial, Capital One, NextSource Materials, Moderna... - Proactive financial news
Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026 - GuruFocus
Moderna stock rises. Revenue in 2025 will be higher than midpoint of guidance - MSN
Moderna updates on business and pipeline at JPM conference - The Pharma Letter
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance. - Barron's
Moderna reiterates target of up to 10% revenue growth in 2026 (MRNA:NASDAQ) - Seeking Alpha
Moderna expects sales near upper end of 2025 forecast - Business Day
Moderna expects $1.9 billion revenue for 2025, exceeds cost targets By Investing.com - Investing.com India
Moderna sees sales boost as Covid-19 shots beat expectations - The Edge Malaysia
Moderna expects full-year 2025 revenue of $1.9B - breakingthenews.net
Moderna expects 2025 revenue of about $1.9 billion - marketscreener.com
Moderna climbs on $1.9 billion 2025 sales forecast - TradingView — Track All Markets
Moderna stock rises as revenue outlook exceeds estimates By Investing.com - Investing.com Canada
Moderna expects $1.9 billion in sales, trims costs forecast for 2025 - Reuters
Moderna raises 2025 revenue forecast to $1.9 billion - StreetInsider
Moderna chair warns of ‘dystopia’ amid US science pullback - Semafor
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - St. Cloud Times
The mRNA Rivalry in 2026: A Tale of Financial Fortress Versus Speculative Despair - AD HOC NEWS
Moderna Vaccine (Spikevax) Review: Why This COVID-19 Shot Still Matters in 2026 - AD HOC NEWS
SG Americas Securities LLC Has $7.46 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - Lincoln Courier
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Greenville Online
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics - FinancialContent
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why - sharewise.com
Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010 - Yahoo Finance
Biotech Co. Says HHS Infringed Patent With Moderna Vax Deal - Law360
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.74%
2.39%
자본화:
|
볼륨(24시간):